Precision medicine research at Karmanos comparing biomarker

A Barbara Ann Karmanos Cancer Institute clinical researcher and her team have received $16,000 to further research in precision medicine for breast cancer treatment. Common Citizen leadership delivered the check to Jailan Elayoubi, M.D. , medical oncologist and member of the Breast Cancer and Phase 1 Clinical Trials Multidisciplinary Teams, in November 2023. Dr. Elayoubi and her team have made significant strides in studying biomarkers and tumor molecular characteristics that may predict sensitivity and

Precision Oncology and Cancer Biomarkers: Issues at Stake and

Over 160 Southeast Michigan residents received cancer screenings and consultations at Karmanos Cancer Institute's screening event

Frontiers Diagnostic Accuracy of Liquid Biomarkers in Airway

From Discovery to Clinical Application: The Role of Biomarkers in

The Evolution of Biomarker Use in Clinical Trials for Cancer

Discovery of primary prostate cancer biomarkers using cross cancer

Karmanos, McLaren offer free, easy-to-use colorectal cancer screening kits at the Summer Safety Fair

Welcome, Dr. Frank - Barbara Ann Karmanos Cancer Institute

IN THE NEWS: How a preemptive cancer screening helped save this

A Randomized, Phase II, Biomarker-Selected Study Comparing

Halabi et al KCJ19n3 2021

A Randomized, Phase II, Biomarker-Selected Study Comparing

Cancer Biomarkers: Powering Precision Medicine